Clinical trials: Bronchiectasis Adult
Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying nodular bronchiectasis and documented MAC lung…
- Conditions
- Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
- Trial name
- CleaR-MAC (NCT04616924)
- Testing
- RHB-204
- Where
- 25 sites in United States
- Volunteers
- 12 people
- Sponsor
- RedHill Biopharma Limited
Chronic Obstructive Pulmonary Disease, Non-cystic Fibrosis Bronchiectasis
A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life
This study aims to evaluate the impact of a specific oral probiotic blend on the quality of life of adults with respiratory conditions.
- Trial name
- NCT05523180
- Testing
- Probiotic
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- ResBiotic Nutrition, Inc.
Non-cystic Fibrosis Bronchiectasis
Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough
This is a randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety and efficacy of ARINA-1 compared to placebo (isotonic saline, 0.9%) in participants with NCFBE.
- Trial name
- NCT05495243
- Testing
- ARINA-1
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Renovion, Inc.
Bronchiectasis Adult, COPD
Evaluation of the Effectiveness of The Volara System Determined by Sputum Movement and Production
The aim of this study is to evaluate the therapeutic effect of therapy with The Volara System on mucus clearance.
- Trial name
- NCT06937216
- Testing
- Volara therapy
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Baxter Healthcare Corporation
Asthma, Bronchiectasis
A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis
The primary objective is to evaluate whether DAS181 is safe in subjects with well-controlled asthma or bronchiectasis.
- Trial name
- DAS181 (NCT01113034)
- Testing
- DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ansun Biopharma, Inc.
Primary Ciliary Dyskinesia
Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.
- Trial name
- NCT05737485
- Testing
- RCT1100
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 9 people
- Sponsor
- ReCode Therapeutics
Primary Ciliary Dyskinesia (PCD)
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
- Trial name
- NCT06633757
- Testing
- RCT1100
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 14 people
- Sponsor
- ReCode Therapeutics
Bronchiectasis
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
The aim of this clinical trial is to assess the safety of: single doses of the study drug CHF6333 in Healthy Volunteers (HVs) and in subjects with Bronchiectasis (BE) - Part I repeated doses of the study drug CHF6333 in subjects…
- Trial name
- NCT06166056
- Testing
- CHF6333
- Where
- 8 sites in United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization
First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients
The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and…
- Conditions
- Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization, Bacterial Infections
- Trial name
- NCT07708116
- Testing
- CTX-187
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Centauri Therapeutics Limited
Cystic Fibrosis, Bronchiectasis
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
This study is open to adults aged 18 years and older with cystic fibrosis bronchiectasis. The purpose of this study is to find out whether a medicine called BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis.
- Trial name
- NCT05865886
- Testing
- BI 1291583
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Bronchiectasis
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
The AIR-BX2 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3…
- Trial name
- AIR-BX2 (NCT01314716)
- Testing
- AZLI
- Where
- 85 sites in United States, Australia and 8 more
- Volunteers
- 274 people
- Sponsor
- Gilead Sciences
Healthy Participants, Non-cystic Fibrosis Bronchiectasis
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled Rev-56 compared to placebo in adult healthy participants and non-cystic fibrosis bronchiectasis (NCFB)…
- Trial name
- NCT07709494
- Testing
- Rev-56 for Inhalation
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Revagenix, Inc.
Bronchiectasis
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
The AIR-BX1 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3…
- Trial name
- AIR-BX1 (NCT01313624)
- Testing
- AZLI
- Where
- 60 sites in United States, Australia and 1 more
- Volunteers
- 266 people
- Sponsor
- Gilead Sciences
Bronchiectasis Adult
Home Airway Clearance in Patients With Bronchiectasis (Home-Care Bronchiectasis)
Bronchiectasis is a chronic multiple etiologies pulmonary disease characterized by permanent dilatation of the caliber of the bronchial tree territory with an alteration of mucociliary clearance.
- Trial name
- NCT04742270
- Testing
- SIMEOX+ respiratory physiotherapy telecare
- Where
- 3 sites in France
- Volunteers
- 22 people
- Sponsor
- Physio-Assist
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Primary Ciliary Dyskinesia
A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
The goal of this observational study is to characterize clinical measures and biomarkers of airway disease in adults with primary ciliary dyskinesia (PCD) and in a group of healthy volunteers (HV) to establish normative values.
- Trial name
- NCT05685186
- Testing
- Spirometry, Multiple Breath Washout (MBW), Mucociliary Clearance (MCC)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- ReCode Therapeutics
Bronchiectasis Adult
Real Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS)
The purpose of this study is to collect data to assess the use of the LibAirty™ System for improving bronchiectasis symptoms and healthcare resource utilization when it is used at home.
- Trial name
- NCT07135284
- Testing
- Airway clearance system
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Synchrony-Medical, Ltd
Bronchiectasis Adult
Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis
This study will evaluate the safety and effects of ALX1, an inhaled investigational treatment, in adults with bronchiectasis. Participants will receive either ALX1 or a placebo (a treatment with no active medicine) for 14 days.
- Trial name
- NCT07731919
- Testing
- ALX1
- Volunteers
- 28 people
- Sponsor
- Vast Therapeutics
Non-cystic Fibrosis Bronchiectasis
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)
- Trial name
- ATMOS (NCT07720375)
- Testing
- Galvokimig
- Where
- 4 sites in United States
- Volunteers
- 300 people
- Sponsor
- UCB Biopharma SRL
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant patient's body from rejecting a transplanted lung or…
- Conditions
- Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT00105183
- Testing
- EZ-2053, EZ-2053 5mg/kg
- Where
- 19 sites in United States, Australia and 2 more
- Volunteers
- 223 people
- Sponsor
- Neovii Biotech